Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/23317
EVALUATION OF GALECTIN-3 AS A NOVEL BIOMARKER FOR CHAGAS CARDIOMYOPATHY
Autor(es)
Afiliação
Hospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil
Hospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, Brasil
Hospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, Brasil
Hospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, Brasil
Hospital São Rafael. Clinical Diagnostics Laboratory. Salvador, BA, Brasil
Hospital São Rafael. Clinical Diagnostics Laboratory. Salvador, BA, Brasil
Center for Biotechnology and Cell Therapy. Salvador, BA, Brasil
Hospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, Brasil
Hospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, Brasil
Hospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, Brasil
Hospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, Brasil
Hospital São Rafael. Clinical Diagnostics Laboratory. Salvador, BA, Brasil
Hospital São Rafael. Clinical Diagnostics Laboratory. Salvador, BA, Brasil
Center for Biotechnology and Cell Therapy. Salvador, BA, Brasil
Hospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, Brasil
Resumo em Inglês
Chagas cardiomyopathy has worse long-term outcomes than other cardiomyopathies. A biomarker strategy to refer subjects for noninvasive cardiac imaging may help in the early identification of cardiac damage in subjects with Chagas disease. Galectin-3 (Gal-3) is a mediator of cardiac fibrosis shown to be upregulated in animal models of decompensated heart failure. Here we assessed the correlation of Gal-3 with myocardial fibrosis in patients with Chagas disease. Methods: This study comprised 61 subjects with
Chagas disease. All subjects underwent clinical assessments,
Doppler echocardiography and magnetic resonance imaging.
Plasmatic Gal-3 was determined by ELISA. Results: Delayed
enhancement (DE) was identified in 37 of 61 subjects
(64%). The total amount of myocardial fibrosis was 9.4% [interquartile
interval (IQI): 2.4–18.4]. No differences were observed
in Gal-3 concentration according to the presence or
absence of myocardial fibrosis, with a median Gal-3 concentration of 11.7 ng/ml (IQI: 9.4–15) in subjects with DE versus
12.9 ng/ml (IQI: 9.2–14) in subjects without DE (p = 0.18). No
correlation was found between myocardial fibrosis and Gal-
3 concentration (r = 0.098; p = 0.47). Conclusions: There is no
correlation between the degree of myocardial fibrosis and
the concentration of Gal-3 in subjects with Chagas disease
Compartilhar